DCVax®-L——由西北生物治疗公司研发。
DCVax®-L--developed by Northwest Biotherapeutics.
作者信息
Polyzoidis Stavros, Ashkan Keyoumars
机构信息
a Department of Neurosurgery; King's College Hospital; King's College ; London , UK.
出版信息
Hum Vaccin Immunother. 2014;10(11):3139-45. doi: 10.4161/hv.29276.
Abstract
Dendritic cell (DC) immunotherapy is emerging as a potential addition to the standard of care in the treatment of glioblastoma multiforme (GBM). In the last decade or so various research groups have conducted phase I and II trials of DC-immunotherapy on patients with newly diagnosed (ND) and recurrent GBM and other high-grade gliomas in an attempt to improve the poor prognosis. Results show an increase in overall survival (OS), while vaccination-related side effects are invariably mild. Northwest Biotherapeutics, Inc., Bethesda, Maryland, U.S.A. (NWBT) developed the DCVax®-L vaccine as an adjunct to the treatment of GBM. It is currently under evaluation in a phase III trial in patients with ND-GBM, which is the only ongoing trial of its kind. In this review current data and perspectives of this product are examined.
摘要
树突状细胞（DC）免疫疗法正在成为多形性胶质母细胞瘤（GBM）治疗标准方案中一种潜在的补充治疗方法。在过去十年左右的时间里，多个研究小组对新诊断（ND）和复发性GBM以及其他高级别胶质瘤患者进行了DC免疫疗法的I期和II期试验，试图改善其不良预后。结果显示总生存期（OS）有所延长，而疫苗接种相关的副作用始终较为轻微。美国马里兰州贝塞斯达的西北生物治疗公司（NWBT）研发了DCVax®-L疫苗作为GBM治疗的辅助手段。目前该疫苗正在针对ND-GBM患者进行III期试验评估，这是此类唯一正在进行的试验。在本综述中，将对该产品的当前数据和观点进行研究。
相似文献
1
DCVax®-L--developed by Northwest Biotherapeutics.
Hum Vaccin Immunother. 2014;10(11):3139-45. doi: 10.4161/hv.29276.
2
DCVax-Brain and DC vaccines in the treatment of GBM.
Expert Opin Investig Drugs. 2009 Apr;18(4):509-19. doi: 10.1517/13543780902841951.
3
The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Hum Vaccin Immunother. 2014;10(11):3322-31. doi: 10.4161/21645515.2014.983002.
4
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6.
5
Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.
CNS Oncol. 2015;4(2):63-9. doi: 10.2217/cns.14.54.
6
A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Trials. 2018 May 25;19(1):293. doi: 10.1186/s13063-018-2659-7.
7
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.
Cancer Immunol Immunother. 2012 Nov;61(11):2033-44. doi: 10.1007/s00262-012-1261-1. Epub 2012 Apr 22.
8
First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax).
Front Immunol. 2024 Aug 13;15:1404861. doi: 10.3389/fimmu.2024.1404861. eCollection 2024.
9
Active dendritic cell immunotherapy for glioblastoma: Current status and challenges.
Br J Neurosurg. 2015 Apr;29(2):197-205. doi: 10.3109/02688697.2014.994473. Epub 2014 Dec 26.
10
Technology evaluation: DCVax, Northwest Biotherapeutics.
Curr Opin Mol Ther. 2002 Aug;4(4):403-7.
引用本文的文献
1
Harnessing immunotherapy: cancer vaccines as novel therapeutic strategies for brain tumor.
Front Immunol. 2025 Jul 17;16:1588081. doi: 10.3389/fimmu.2025.1588081. eCollection 2025.
2
Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature.
Clin Transl Oncol. 2024 Dec 23. doi: 10.1007/s12094-024-03830-9.
3
Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines.
Front Immunol. 2024 Aug 14;15:1438030. doi: 10.3389/fimmu.2024.1438030. eCollection 2024.
4
Revisiting the standards of cancer detection and therapy alongside their comparison to modern methods.
World J Methodol. 2024 Jun 20;14(2):92982. doi: 10.5662/wjm.v14.i2.92982.
5
Current approaches in glioblastoma multiforme immunotherapy.
Clin Transl Oncol. 2024 Jul;26(7):1584-1612. doi: 10.1007/s12094-024-03395-7. Epub 2024 Mar 21.
6
Glioblastoma Therapy: Past, Present and Future.
Int J Mol Sci. 2024 Feb 21;25(5):2529. doi: 10.3390/ijms25052529.
7
Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer.
Pharmaceuticals (Basel). 2023 Sep 29;16(10):1384. doi: 10.3390/ph16101384.
8
The Potential of Dendritic Cell Subsets in the Development of Personalized Immunotherapy for Cancer Treatment.
Curr Issues Mol Biol. 2023 Oct 1;45(10):8053-8070. doi: 10.3390/cimb45100509.
9
DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open.
Cancers (Basel). 2023 Jun 20;15(12):3251. doi: 10.3390/cancers15123251.
10
Immunotherapy: A new target for cancer cure (Review).
Oncol Rep. 2023 May;49(5). doi: 10.3892/or.2023.8537. Epub 2023 Mar 31.
本文引用的文献
1
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge.
Nat Rev Cancer. 2014 Feb;14(2):92-107. doi: 10.1038/nrc3655.
2
Immunotherapeutic approaches to hepatocellular carcinoma treatment.
Liver Cancer. 2012 Nov;1(3-4):226-37. doi: 10.1159/000343837.
3
Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma.
J Neuroimmunol. 2013 Dec 15;265(1-2):106-16. doi: 10.1016/j.jneuroim.2013.09.011. Epub 2013 Sep 20.
4
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9.
5
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma.
Cancer Immunol Immunother. 2013 Sep;62(9):1499-509. doi: 10.1007/s00262-013-1453-3. Epub 2013 Jul 2.
6
α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
BMC Cancer. 2012 Dec 27;12:623. doi: 10.1186/1471-2407-12-623.
7
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.
Cancer Immunol Immunother. 2013 Jan;62(1):125-35. doi: 10.1007/s00262-012-1319-0. Epub 2012 Jul 31.
8
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.
Cancer Immunol Immunother. 2012 Nov;61(11):2033-44. doi: 10.1007/s00262-012-1261-1. Epub 2012 Apr 22.
9
Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial.
World Neurosurg. 2012 May-Jun;77(5-6):736-44. doi: 10.1016/j.wneu.2011.08.020. Epub 2011 Nov 7.
10
Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma.
Cell Biochem Biophys. 2012 Jan;62(1):91-9. doi: 10.1007/s12013-011-9265-6.
Zotero 插件